-
2 months ago | 
lithub.com | Alok Khorana
It was my first visit to Tokyo. Thanks to a lost-in-translation miscommunication with my scientific colleagues, I found myself with an unexpectedly open daytime schedule. This is how I ended up alone at the Tokyo National Museum one brisk fall weekday morning in 2019, in front of a group of 5th century CE sculptures with what seemed to my uneducated eye to be distinctly Indian aesthetics: upraised palms, multiple arms, lotus symbols.
-
Feb 6, 2025 | 
targetedonc.com | Rahul Gosain |Rohit Gosain |Alok Khorana
Experts discuss the CheckMate 8HW study, focusing on its design, key findings, and impact on treatment strategies.
-
Feb 6, 2025 | 
targetedonc.com | Rahul Gosain |Rohit Gosain |Alok Khorana
Experts discuss an overview of the BREAKWATER study, highlighting its key objectives, findings, and implications.
-
Feb 6, 2025 | 
targetedonc.com | Rahul Gosain |Rohit Gosain |Alok Khorana
Experts discuss an overview of the STARTER-NET study, emphasizing its goals, key outcomes, and potential impact on clinical practice.
-
Jan 9, 2025 | 
medrxiv.org | Anthony Sloan |Alan J. Gordillo |Austin Kennemer |Alok Khorana
The author declare no conflicts of interest. JDL is listed as an inventor on intellectual property related to cancer therapies, but this is not directly relevant to this work. This work is supported by a cancer biology training grant NIH T32 CA059366 (To ARS), Ruth L. Kirschstein Postdoctoral NRSA NIH F32 CA287655 (To ARS), and the Midwest Brain Tumor Foundation Postdoctoral Fellowship (To ARS), NIH HL158801 (to SJC).
-
May 28, 2024 | 
newswise.com | Alok Khorana
Newswise — The rise in early-onset gastrointestinal cancers includes an increased risk of pancreatic adenocarcinoma (PDAC), but the underlying pathogenesis is incompletely understood. The tumor microbiome is an increasing focus of research given its impact on tumor pathogenesis and outcomes. We evaluated microbiome profiles in resected specimens from early-onset PDAC (eoPDAC) and average-onset PDAC (aoPDAC).
-
Feb 1, 2024 | 
ccjm.org | Heloni Dave |Alok Khorana
KEY POINTS Patients with cancer are at a much higher risk of developing VTE than the general population. Low-molecular-weight heparin or direct oral anticoagulants are preferred over vitamin K antagonists. Direct oral anticoagulants are generally preferred, but caution is needed in patients at risk of bleeding.
-
Dec 15, 2023 | 
cancernetwork.com | Suneel Kamath |Joanna Roopkumar |Ying Ni |Minqian Shen |Pablo G. Bejarano |Daniela Allende | +9 more
December 15, 2023OncologyONCOLOGY Vol 37, Issue 12Pages: 488-495Suneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer. ABSTRACTIntroduction: Exceptional response to therapy is rare in patients with advanced pancreatic cancer. This study explored potential genomic differences between typical and exceptional responses that could confer more favorable biology.
-
Dec 15, 2023 | cancernetwork.com | Suneel Kamath |Joanna Roopkumar |Ying Ni |Minqian Shen |Pablo G. Bejarano |Daniela Allende | +9 more
December 15, 2023OncologyONCOLOGY Vol 37, Issue 12Pages: 488-495Suneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer. ABSTRACTIntroduction: Exceptional response to therapy is rare in patients with advanced pancreatic cancer. This study explored potential genomic differences between typical and exceptional responses that could confer more favorable biology.
-
Dec 15, 2023 | cancernetwork.com | Suneel Kamath |Joanna Roopkumar |Ying Ni |Minqian Shen |Pablo G. Bejarano |Daniela Allende | +9 more
December 15, 2023OncologyONCOLOGY Vol 37, Issue 12Pages: 488-495Suneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer. ABSTRACTIntroduction: Exceptional response to therapy is rare in patients with advanced pancreatic cancer. This study explored potential genomic differences between typical and exceptional responses that could confer more favorable biology.
